Re: Policy makers' perception of NVAX
This is somewhat misleading, as it refers to doses manufactured at CEPI funded facilities. There is almost no doubt that SII could provide any number of doses desired into the 100s of millions.
Novavax's failure goes back to trying to bring too many facilities online at the same time, resulting in none of the facilities being ready when needed. To date only SII, SK Bio and Takeda have been authorized to manufacture finished product almost 3 years into the pandemic.